

Jun. 13. 2002 2:50PM

MARSHALL, GERSTEIN & BORUN

No. 0178
FAX RECEIVED

P. 1/5

JUN 14 2002

#4
ms
6/18/02

MARSHALL, GERSTEIN & BORUN **GROUP 1600**

ATTORNEYS AT LAW

6300 SEARS TOWER

233 SOUTH WACKER DRIVE

CHICAGO, ILLINOIS 60606-6357

(312) 474-6300

FAX: (312) 474-0448

OFFICIAL

June 13, 2002

FACSIMILE TRANSMISSION SHEET

TO Group 1600
COMPANY Patent and Trademark
Office
FAX NO. 1-703-872-9306
PHONE NO.

FROM: Sharon M. Sintich

EXTENSION: 818

PAGES (INCLUDING THIS PAGE): 5

CLIENT NO: 28110

MATTER NO: 35878A

PLEASE CONFIRM RECEIPT: Yes

COUNTRY CODE: US

MESSAGE:

Serial No. 10/082,902

Please contact Jill L. Schumerth at (312) 474-6818 if you do not receive all of the pages in good condition.

The material of this transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. 1-703-872-8308, on the date shown below.

Dated: June 13, 2002

Signature:

(Sharon M. Shlich)

Docket No.: 28110/35878A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Dennis G. Ballinger, et al.

Application No.: 10/082,902

Group Art Unit: 1647

Filed: February 26, 2002

Projected Examiner: C. Saoud

For: GROWTH FACTOR ANTAGONIST
MATERIALS AND METHODS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Submitted herewith is a form PTO/SB/08 listing several documents. Copies of all documents have been submitted in the parent application no. 09/370,398 filed August 6, 1999 and thus pursuant to 37 CFR §1.98(d), copies are not submitted herewith.

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 USC §102 or §103.

Application No.: 10/082,902


Docket No.: 28110/35878A

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed to be due under 37 CFR §1.97 (b) because this statement and form PTO/SB/08 are being submitted before receipt of a first office action on the merits in the above-identified patent application. However, the Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: June 13, 2002

Respectfully submitted,

By 
Sharon M. Sintich
Registration No. 48,484
MARSHALL, GERSTEIN & BORUN
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicant

PTO/SB/D&A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/082,902
		Filing Date	February 26, 2002
		First Named Inventor	Dennis G. Ballinger
		Art Unit	1647
		Examiner Name	Not Yet Assigned
Sheet 1 of 2	Attorney Docket Number	28110/35878A	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	A	-WO 00/15781-	03-23-2000			
	B	-WO 98/20032-	05-14-1998			

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C	CASCI <i>et al.</i> , <i>Sprouty, an Intracellular Inhibitor of Ras Signaling</i> , Cell 96(5): 655-665 (March 1999).	
	D	de MAXIMY <i>et al.</i> , <i>Cloning and Expression Pattern of a Mouse Homologue of Drosophila Sprouty in the Mouse Embryo</i> , Mechanisms of Development 81: 213-216 (1999).	
	E	HACOHEN <i>et al.</i> , <i>Sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways</i> , Cell 92: 253-263 (January 23, 1998).	
	F	IMPAGNATIELLO <i>et al.</i> , <i>Mammalian Sprouty-1 and -2 Are Membrane-Anchored Phosphoprotein Inhibitors of Growth Factor Signaling in Endothelial Cells</i> , The Journal of Cell Biology 152(5): 1087-1098 (March 5, 2001).	
	G	KRAMER <i>et al.</i> , <i>Sprouty: a Common Antagonist of FGF and EGF Signaling Pathways in Drosophila</i> , Development 126: 2515-2525 (May 1999).	
	H	LEE <i>et al.</i> , <i>Inhibition of Angiogenesis by a Mouse Sprouty Protein</i> , The Journal of Biological Chemistry 276(6): 4128-4133 (February 9, 2001).	
	I	METZGER <i>et al.</i> , <i>Genetic Control of Branching Morphogenesis</i> , Science 284: 1635-1639 (June 4, 1999).	
	J	MINOWADA <i>et al.</i> , <i>Vertebrate Sprouty Genes are Induced by FGF Signaling and can Cause Chondrodysplasia When Overexpressed</i> , Development 126: 4485-4475 (September 27, 1999).	
	K	PLACZEK and SKAER, <i>Airway Patterning: A Paradigm for Restricted Signaling</i> , Current Biology 9: R506-R510 (1999).	
	L	REICH <i>et al.</i> , <i>Sprouty is a General Inhibitor of Receptor Tyrosine Kinase Signaling</i> , Development 126: 4139-4147 (August 23, 1999).	
	M	TEFFT <i>et al.</i> , <i>Conserved Function of mSpry-2, a Murine Homolog of Drosophila Sprouty, Which Negatively Modulates Respiratory Organogenesis</i> , Current Biology 9: 219-222 (1999).	
	N	WONG <i>et al.</i> , <i>Evidence for Direct Interaction Between Sprouty and Cbl</i> , The Journal of Biological Chemistry 276(8): 5866-5875 (February 23, 2001).	
	O	LIM <i>et al.</i> , <i>Sprouty Proteins Are Targeted to Membrane Ruffles upon Growth Factor Receptor Tyrosine Kinase Activation</i> , The Journal of Biological Chemistry 275(42): 32837-32845 (October 20, 2000).	

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/082,902
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	February 26, 2002
		First Named Inventor	Dennis G. Ballinger
		Group Art Unit	1647
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	28110/35878A
Sheet	2	of	2

P	SASAKI et al., Identification of a Dominant Negative Mutant of Sprouty That Potentiates Fibroblast Growth Factor-but Not Epidermal Growth Factor-induced ERK Activation, The Journal of Biological Chemistry 276(39): 36804-36808 (September 28, 2001).
Q	YIGZAW et al., The C Terminus of Sprouty Is Important for Modulation of Cellular Migration and Proliferation, The Journal of Biological Chemistry 276(25): 22742-22747 (June 22, 2001).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.